Les compartimos la información del próximo Congreso Latinoamericano de Hematopatologia. Será un gusto poder saludarnos en Guatemala ! Y compartir y actualizarnos.🔬
CLL12 study supports using the watch-and-wait approach as the standard of care for early-stage CLL, including high-risk patients. Ongoin @SWOG S1925 trial evaluates early venetoclax-based treatment for high risk patients. @JCO_ASCO@DebbieMStephens https://t.co/3JgtkGjwlt
Sequencing of therapy for patients with diffuse large B-cell lymphoma in the era of novel drugs - British Journal of Haematology | Wiley Online Library
https://t.co/OUTUfFY3FA
CONGRESS | #SOHO2024
Christopher Yasenchak, Willamette Valley Cancer Institute, shares results from the phase III ECHELON-3 study of brentuximab vedotin in combination with len and rituximab for R/R DLBCL.
Median PFS 4.2 mo, OS 13.8 mo, ORR 64%, CR 40%, AEs were managed with dose modifications and were consistent with individual known safety profiles.
#lymsm
Results of the phase III SYMPATICO trial presented at #ASCO24 show that ibrutinib + venetoclax is effective for the treatment of pts with MCL & TP35 mutations, with high CR rates & durable remissions 📝
More news: https://t.co/w5gdqqEJhi
#lymphoma#MedNews#MedEd@michaelwangmd
Vitamin D supplement for patients with early-stage chronic lymphocytic leukemia is associated with a longer time to first treatment
https://t.co/INx17iediO
Diffuse large B-cell lymphoma at risk of secondary CNS involvement: The inefficacy of IV HD-methotrexate CNS prophylaxis & the importance of baseline cerebrospinal fluid analysis [May 10, 2023] Bennett et al. @AjHematology https://t.co/i25YCeHqXI #lymsm#btsm#CNSprophylaxis
🔴Atrial Fibrillation and Cirrhosis: Which Anticoagulant?
🔹Apixaban might present less bleeding risk than rivaroxaban or warfarin.
🔹Apixaban is associated with a roughly 3-percentage-point lower incidence of bleeding events annually
✔️https://t.co/aQY1FDHnc3
🖍️Infografías sobre monitorización y ajuste posológico en antifúngicos:
👉Rol de la monitorización en triazólicos
👉Recomendaciones para cada formulación
👉T de muestreo
👉Nivls valle recomendados
👉Ajustes de D en itra, posa, vori e isavuconazol
From:
https://t.co/PhlVD5RPSa
🚨"Risk of infections with bispecific antibodies in B-cell non-Hodgkin lymphomas and multiple myeloma—The current state.”
The review summarizes @US_FDA Approved BsAb. Work led by PGY1 IM, @AmritGonugunta@BrJHaem@MDAndersonNews#BiTE#CART#infections
https://t.co/sWQK3tXaCJ
Good news for follicular lymphoma patients: #epcoritamab receives positive conditional marketing approval from CHMP/EMA based on phase II NHL-1 study results. Another CD20 x CD3 bispecific antibody available
https://t.co/QYIN5WQI8P
#lymSM
Prepárate para una experiencia de aprendizaje, networking y buena onda en la 2da jornada del GCEL!
26 y 27 de Julio 2024
Double tree by Hilton , av. Kennedy 4422, Vitacura
Únete a nosotros y forma parte del cambio en el tratamiento de los linfomas. ¡No faltes!
Fecha: [26 y 27 de Julio]
Horario: [8:30 am ]
Lugar: [Hotel DoubleTree by Hilton. Av. Kennedy Lateral 4422, Vitacura]
¡Inscríbete ya y asegura tu cupo en este importante evento del mundo de la hematología y la oncología! #GCEL#Linfoma#Networking#Hematología
¡No te pierdas la segunda jornada del Grupo Chileno de Estudio del Linfoma (GCEL)!
Te invitamos a participar de esta imperdible cita que reunirá a algunos de los profesionales más destacados en el estudio y tratamiento del linfoma en Chile y en Latinoamérica.